Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK-MEDCO ADDS GENERIC CIMETIDINE TO ULCER THERAPY PROGRAM

Executive Summary

MERCK-MEDCO ADDS GENERIC CIMETIDINE TO ULCER THERAPY PROGRAM through West Point Pharma, which is distributing the generic version of SmithKline Beecham's Tagamet manufactured by DuPont Merck's Endo Labs. The Merck-Medco program, which is marketing a per capita formula for providing drug therapy to ulcer patients ("The Pink Sheet" Jan. 31, p. 3), will add the generic cimetidine to its line of antiulcer medications, which includes the company's H[2] antagonist Pepcid and the proton pump inhibitor Prilosec. Merck-Medco said it will continue to make Tagamet available in the program at a low cost under preferred drug contracts with SmithKline Beecham.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel